Lupin Limited (LUPIN) — Financial Results | 27 June 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Lupin Limited reported a 69.9% year-on-year increase in net profit to ₹87.22 crores for the quarter ended June 30, 2025, driven by strong performance in its domestic formulation segment, while revenue growth remained muted at 32% YoY to ₹1,245.6 crores. The company announced a temporary trading window closure ahead of its upcoming unaudited results declaration, with no forward guidance provided on future performance.

📄 View Original Announcement (PDF)

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

📊 More LUPIN filings

See all LUPIN filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track LUPIN — Free

Free account · 2 AI queries/day